Salmonella enterica

Patent Granted The subject of the offer is a new vaccine-based cancer therapy based on genetically modified bacterial strain of Salmonella VNP20009 that is able to target tumour tissue. Tumour targeting was enhanced by antibody fragments specific to carcinoembryonic antigen. Further genetic modifications were introduced to increase apoptosis and necrosis within the tumour microenvironment, resulting in augmented cancer-specific immunity. The vaccine exhibited potent efficiency in animal studies.; Patent family with 3 members; http://en.wikipedia.org/wiki/Salmonella_enterica